EIC Fund invested companies

First-in-class therapy development addressing unmet medical needs in the oncology space

A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO

Developer of antithrombotic drugs for vascular complications.

Developer of dementia and dermatology drugs via genomics.

Anti-microRNAs designed for the treatment of diseases with unmet needs.

Pharmaceutical company focused on the small molecule drug NTP42 for the treatment of pulmonary arterial hypertension (PAH).

Next generation of insulin-producing cell transplantation

Developer first-in-class therapies for neurodegenerative diseases.

Disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier

The company develops compact, affordable automatic bio-decontamination systems based on proprietary solid hydrogen peroxide technology to eliminate harmful microorganisms in labs, hospitals, and other critical environments.

First-in-class disease-modifying drug for chronic airway disorders

Pioneer in exosome-based regenerative therapies.

Developing novel treatments for medical conditions with unmet needs

Pioneering advanced technologies aimed at revolutionising immune reconstitution for patients with severe immune deficiencies.

Clinical-stage biotechnology disease modifying therapies for neurodegenerative diseases

Treating cancer by targeting tumor viruses within the human genome

Innovative treatments for chronic pain disorders and hearing loss.